Updated on 2021/11/02

写真a

 
WATANABE Takahiro
 
Organization
Graduate School of Medicine Program in Integrated Medicine Microbiology and Immunology Assistant Professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Assistant Professor
Contact information
メールアドレス

Degree 1

  1. 博士(医学) （ 2016.3   名古屋大学 ） 

To the head of Degree.▲

Research Interests 3

  1. 口腔外科学

  2. ウイルス学

  3. 腫瘍ウイルス学

To the head of Research Interests.▲

Research Areas 2

  1. Life Science / Surgical dentistry

  2. Life Science / Virology

To the head of Research Areas.▲

Research History 6

  1. Nagoya University   Assistant

    2017.10

    　 More details

    Country：Japan

  2. Aichi Gakuin University

    2017.1

    　 More details

    Country：Japan

  3. Nagoya University

    2016.4 - 2017.9

    　 More details

    Country：Japan

  4. Fujita Health University

    2013.4

    　 More details

    Country：Japan

  5. Fujita Health University   Assistant

    2011.4 - 2013.3

    　 More details

    Country：Japan

  6. 浜松医療センター   臨床研修歯科医師

    2009.4 - 2011.3

    　 More details

    Country：Japan

▼display all

To the head of Research History.▲

Education 1

  1. Nagoya University   Graduate School, Division of Medical Sciences

    - 2016.3

    　 More details

    Country： Japan

To the head of Education.▲

Professional Memberships 5

  1. 日本有病者歯科医療学会   専門医

  2. 日本口腔外科学会   認定医

  3. 日本ウイルス学会

  4. 日本癌学会

  5. 日本臨床ウイルス学会

To the head of Professional Memberships.▲

Awards 1

  1. 優秀ポスター発表賞

    2017.10   第62回日本口腔外科学会総会学術大会  

    渡辺　崇広

To the head of Awards.▲
 

Papers 28

  1. A STING inhibitor suppresses EBV-induced B cell transformation and lymphomagenesis. International journal

    Shouhei Miyagi, Takahiro Watanabe, Yuya Hara, Masataka Arata, Md Kamal Uddin, Keisuke Mantoku, Ken Sago, Yusuke Yanagi, Takeshi Suzuki, H M Abdullah Al Masud, Jun-Ichi Kawada, Shigeo Nakamura, Yasuyuki Miyake, Yoshitaka Sato, Takayuki Murata, Hiroshi Kimura

    Cancer science     2021.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is frequently fatal. Innate immunity plays a key role in protecting against pathogens and cancers. The stimulator of interferon genes (STING) is regarded as a key adaptor protein allowing DNA sensors recognizing exogenous cytosolic DNA to activate the type I interferon signaling cascade. In terms of EBV tumorigenicity, the role of STING remains elusive. Herein we showed that treatment with the STING inhibitor, C-176, suppressed EBV-induced transformation in peripheral blood mononuclear cells. In an EBV-LPD mouse model, C-176 treatment also inhibited tumor formation and prolonged survival. Treatment with B cells alone did not affect EBV transformation, but suppression of EBV-induced transformation was observed in the presence of T cells. Even without direct B cell-T cell contact in a Transwell system, the inhibitor reduced the transformation activity, indicating that intercellular communication by humoral factors was critical to prevent EBV-induced transformation. These findings suggest that inhibition of STING signaling pathway with C-176 could be a new therapeutic target of EBV-LPD.

    DOI： 10.1111/cas.15152

    Web of Science

    PubMed

  2. Deletion of Viral microRNAs in the Oncogenesis of Epstein-Barr Virus-Associated Lymphoma

    Kimura Hiroshi, Okuno Yusuke, Sato Yoshitaka, Watanabe Takahiro, Murata Takayuki

    FRONTIERS IN MICROBIOLOGY   Vol. 12   page： 667968   2021.7

    　More details

    Language：Japanese   Publisher：Frontiers in Microbiology  

    Epstein–Barr virus (EBV), which encodes >80 genes and nearly 50 non-coding RNAs, is a double-stranded DNA virus. EBV is associated with various types of lymphomas and lymphoproliferative disorders not only of B-cell but also T/NK-cell origin. However, the oncogenic mechanism remains poorly understood, including the EBV receptors expressed on T/NK cells, relationship of EBV with host genes, and epigenetic regulation of EBV and host genes. The roles of host and viral non-coding RNAs during tumorigenesis have been elucidated. EBV encodes at least 49 mature microRNAs (miRNAs), of which 44 are located in BamHI-A rightward transcripts (BARTs) region, and the remaining five are located in BamHI-H rightward fragment 1. BART miRNAs modulate cell differentiation, proliferation, apoptosis, and the cell cycle, and they are considered positive regulators of oncogenesis. We and others have recently reported that EBV-positive lymphomas frequently possess large deletions in BART miRNA clusters, suggesting that some viral miRNAs have suppressive effects on oncogenesis, and that deletion of these miRNAs may aid lymphoma formation.

    DOI： 10.3389/fmicb.2021.667968

    Web of Science

    Scopus

    PubMed

  3. RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. Reviewed International journal

    Yusuke Yanagi, Yusuke Okuno, Yohei Narita, H M Abdullah Al Masud, Takahiro Watanabe, Yoshitaka Sato, Teru Kanda, Hiroshi Kimura, Takayuki Murata

    Virology   Vol. 557   page： 44 - 54   2021.5

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    Epstein-Barr virus (EBV) is a causative agent of infectious mononucleosis and several types of malignancy. RNAseq of peripheral blood primary B cell samples infected with wild-type EBV revealed that expression of programmed cell death ligand-1 (PD-L1) is markedly induced by infection. This induction of PD-L1 was alleviated by knockout of the EBNA2 gene, but knockout of LMP1 had little effect. ChIPseq, ChIA-PET, and reporter assays further confirmed that EBNA2-binding sites in the promoter region and at 130 kb downstream of the PD-L1 gene played important roles in PD-L1 induction. Our results indicate that EBV mainly utilizes the EBNA2 gene for induction of PD-L1 and to evade host immunity on infection of primary B cells. Furthermore, pathway analysis revealed that genes involved in the cell cycle, metabolic processes, membrane morphogenesis, and vesicle regulation were induced by EBNA2, and that EBNA2 suppressed genes related to immune signaling.

    DOI： 10.1016/j.virol.2021.02.004

    Web of Science

    Scopus

    PubMed

  4. Anti-tumor effect of IL2-expressing HSV amplicon vector and oncolytic virus HF10 Reviewed International journal

    Esaki Shinichi, Goshima Fumi, Takano Gaku, Watanabe Takahiro, Sato Yoshitaka, Murata Takayuki, Kimura Hiroshi

    CANCER SCIENCE   Vol. 112   page： 394 - 394   2021.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

  5. Role of Epstein-Barr Virus C Promoter Deletion in Diffuse Large B Cell Lymphoma. Reviewed International coauthorship International journal

    Seiyo Mabuchi, Fumiya Hijioka, Takahiro Watanabe, Yusuke Yanagi, Yusuke Okuno, H M Abdullah Al Masud, Yoshitaka Sato, Takayuki Murata, Hiroshi Kimura

    Cancers   Vol. 13 ( 3 ) page： 561 - 561   2021.2

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：{MDPI} {AG}  

    The Epstein-Barr virus (EBV) is the cause of several malignancies, including diffuse large B cell lymphoma (DLBCL). We recently found that EBV genomes in EBV-positive cancer specimens have various deletions (Okuno et al. Nat Microbiol. 2019). Here, we focus on the deletion of C promoter (Cp), which transcribes EBV nuclear antigen (EBNA) genes in type III latency. The Cp deletion found in a DLBCL patient (332 bp) was introduced into EBV-BAC of the B95-8 strain. Interestingly, the dCp virus transformed B cells more efficiently than WT and revertant strains. Deletion of Cp also promoted tumor formation and severe pathogenicity in a mouse xenograft model. RNA sequencing and qRT-PCR analyses revealed that Cp transcription was undetectable in the dCp cells. Instead, transcription from the W promoter (Wp), an alternative promoter for EBNA, was activated in the dCp mutant. We also found that the expression of latent membrane protein 2A (LMP2A) was somehow induced in the dCp mutant. Double knockout of Cp and LMP2A indicated that LMP2A is crucial for B cell transformation, but the increased transformation induced by Cp deletion cannot be explained by LMP2A alone. We also tested the effect of an anti-apoptotic viral BCL2 homolog, BHRF1, because its expression was reportedly induced more efficiently by that of Wp. However, increased growth transformation via Cp deletion was not due to the BHRF1 gene. Taken together, the results indicated that deletion of a specific region in Cp increased in vitro transformation and the rate of progression of EBV-positive lymphoproliferative disorders in vivo. Our data suggest that genomic alteration not only of the host but also the virus promotes EBV-positive tumor generation and expansion, although the molecular mechanism underlying this phenomenon is still unclear. However, LMP2A and BHRF1 are not involved.

    DOI： 10.3390/cancers13030561

    Web of Science

    Scopus

    PubMed

  6. Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection Reviewed International journal

    Inagaki Tomoki, Sato Yoshitaka, Ito Jumpei, Takaki Mitsuaki, Okuno Yusuke, Yaguchi Masahiro, Al Masud H. M. Abdullah, Watanabe Takahiro, Sato Kei, Iwami Shingo, Murata Takayuki, Kimura Hiroshi

    FRONTIERS IN MICROBIOLOGY   Vol. 11   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Frontiers in Microbiology  

    DOI： 10.3389/fmicb.2020.575255

    Web of Science

    Scopus

  7. Oncolytic activity of HF10 in head and neck squamous cell carcinomas Reviewed International journal

    Shinichi Esaki, Fumi Goshima, Haruka Ozaki, Gaku Takano, Yoshimi Hatano, Daisuke Kawakita, Kei Ijichi, Takahiro Watanabe, Yoshitaka Sato, Takayuki Murata, Hiromitsu Iwata, Yuta Shibamoto, Shingo Murakami, Yukihiro Nishiyama, Hiroshi Kimura

    Cancer Gene Therapy   Vol. 27 ( 7-8 ) page： 585 - 598   2020.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media {LLC}  

    DOI： 10.1038/s41417-019-0129-3

    Web of Science

    Scopus

    PubMed

  8. Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders. Reviewed International journal

    Watanabe T, Sato Y, Masud HMAA, Takayama M, Matsuda H, Hara Y, Yanagi Y, Yoshida M, Goshima F, Murata T, Kimura H

    Cancer science   Vol. 111 ( 1 ) page： 279 - 287   2020.1

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/cas.14241

    Web of Science

    Scopus

    PubMed

  9. Epstein-Barr Virus BBRF2 Is Required for Maximum Infectivity. Reviewed International journal

    Masud HMAA, Yanagi Y, Watanabe T, Sato Y, Kimura H, Murata T

    Microorganisms   Vol. 7 ( 12 )   2019.12

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.3390/microorganisms7120705

    Web of Science

    Scopus

    PubMed

  10. The BOLF1 gene is necessary for effective Epstein-Barr viral infectivity

    Al Masud H. M. Abdullah, Watanabe Takahiro, Sato Yoshitaka, Goshima Fumi, Kimura Hiroshi, Murata Takayuki

    VIROLOGY   Vol. 531   page： 114-125   2019.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.virol.2019.02.015

    Web of Science

    Scopus

    PubMed

  11. Initial Characterization of the Epstein-Barr Virus BSRF1 Gene Product

    Yanagi Yusuke, Al Masud H. M. Abdullah, Watanabe Takahiro, Sato Yoshitaka, Goshima Fumi, Kimura Hiroshi, Murata Takayuki

    VIRUSES-BASEL   Vol. 11 ( 3 )   2019.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3390/v11030285

    Web of Science

    Scopus

    PubMed

  12. Defective Epstein-Barr virus in chronic active infection and haematological malignancy

    Okuno Yusuke, Murata Takayuki, Sato Yoshitaka, Muramatsu Hideki, Ito Yoshinori, Watanabe Takahiro, Okuno Tatsuya, Murakami Norihiro, Yoshida Kenichi, Sawada Akihisa, Inoue Masami, Kawa Keisei, Seto Masao, Ohshima Koichi, Shiraishi Yuichi, Chiba Kenichi, Tanaka Hiroko, Miyano Satoru, Narita Yohei, Yoshida Masahiro, Goshima Fumi, Kawada Jun-Ichi, Nishida Tetsuya, Kiyoi Hitoshi, Kato Seiichi, Nakamura Shigeo, Morishima Satoko, Yoshikawa Tetsushi, Fujiwara Shigeyoshi, Shimizu Norio, Isobe Yasushi, Noguchi Masaaki, Kikuta Atsushi, Iwatsuki Keiji, Takahashi Yoshiyuki, Kojima Seiji, Ogawa Seishi, Kimura Hiroshi

    NATURE MICROBIOLOGY   Vol. 4 ( 3 ) page： 404-413   2019.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41564-018-0334-0

    Web of Science

    Scopus

    PubMed

  13. Publisher Correction: Defective Epstein-Barr virus in chronic active infection and haematological malignancy.

    Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, Inoue M, Kawa K, Seto M, Ohshima K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Narita Y, Yoshida M, Goshima F, Kawada JI, Nishida T, Kiyoi H, Kato S, Nakamura S, Morishima S, Yoshikawa T, Fujiwara S, Shimizu N, Isobe Y, Noguchi M, Kikuta A, Iwatsuki K, Takahashi Y, Kojima S, Ogawa S, Kimura H

    Nature microbiology   Vol. 4 ( 3 ) page： 544   2019.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41564-019-0387-8

    Scopus

    PubMed

  14. Oncolytic activity of HF10 for head and neck squamous cell carcinomas

    Esaki Shinichi, Goshima Fumi, Takano Gaku, Watanabe Takahiro, Sato Yoshitaka, Murata Takayuki, Kimura Hiroshi

    CANCER SCIENCE   Vol. 109   page： 275-275   2018.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

  15. Oncolytic effect of HF10 for breast cancer lung metastasis

    Goshima Fumi, Esaki Shinichi, Takano Gaku, Watanabe Takahiro, Sato Yoshitaka, Murata Takayuki, Kimura Hiroshi

    CANCER SCIENCE   Vol. 109   page： 1038-1038   2018.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

  16. Oncolytic activity of HF10 for head and neck squamous cell carcinomas International journal

    Esaki Shinichi, Goshima Fumi, Takano Gaku, Watanabe Takahiro, Sato Yoshitaka, Murata Takayuki, Kimura Hiroshi

    CANCER SCIENCE   Vol. 109   page： 275-275   2018.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  17. The Presence of Defective Epstein-Barr Virus (EBV) Infection in Patients with EBV-Associated Hematological Malignancy

    Okuno Yusuke, Murata Takayuki, Sato Yoshitaka, Muramatsu Hideki, Ito Yoshinori, Watanabe Takahiro, Okuno Tatsuya, Murakami Norihiro, Yoshida Kenichi, Sawada Akihisa, Inoue Masami, Kawa Keisei, Seto Masao, Ohshima Koichi, Shiraishi Yuichi, Chiba Kenichi, Tanaka Hiroko, Miyano Satoru, Narita Yohei, Yoshida Masahiro, Goshima Fumi, Kawada Junichi, Nishida Tetsuya, Kiyoi Hitoshi, Kato Seiichi, Nakamura Shigeo, Morishima Satoko, Fujiwara Shigeyoshi, Shimizu Norio, Isobe Yasushi, Noguchi Masaaki, Kikuta Atsushi, Iwatsuki Keiji, Takahashi Yoshiyuki, Kojima Seiji, Ogawa Seishi, Kimura Hiroshi

    BLOOD   Vol. 132   2018.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/blood-2018-99-113801

    Web of Science

  18. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.

    Kawada JI, Ando S, Torii Y, Watanabe T, Sato Y, Ito Y, Kimura H

    Cancer medicine     2018.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/cam4.1311

    PubMed

  19. Epstein-Barr Virus BKRF4 Gene Product Is Required for Efficient Progeny Production. Reviewed

    Masud HMAA, Watanabe T, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T

    Journal of virology   Vol. 91 ( 23 )   2017.12

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1128/JVI.00975-17

    PubMed

  20. The Epstein-Barr Virus BRRF1 Gene Is Dispensable for Viral Replication in HEK293 cells and Transformation. Reviewed

    Yoshida M, Watanabe T, Narita Y, Sato Y, Goshima F, Kimura H, Murata T

    Scientific reports   Vol. 7 ( 1 ) page： 6044   2017.7

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-017-06413-7

    PubMed

  21. The C-Terminus of Epstein-Barr Virus BRRF2 Is Required for its Proper Localization and Efficient Virus Production. Reviewed

    Watanabe T, Sakaida K, Yoshida M, Masud HM, Sato Y, Goshima F, Kimura H, Murata T

    Frontiers in microbiology   Vol. 8   page： 125   2017

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.3389/fmicb.2017.00125

    PubMed

  22. Characterization of a Suppressive Cis-acting Element in the Epstein-Barr Virus LMP1 Promoter. Reviewed

    Yoshida M, Murata T, Ashio K, Narita Y, Watanabe T, Masud HMAA, Sato Y, Goshima F, Kimura H

    Frontiers in microbiology   Vol. 8   page： 2302   2017

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.3389/fmicb.2017.02302

    PubMed

  23. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Reviewed

    Ando S, Kawada JI, Watanabe T, Suzuki M, Sato Y, Torii Y, Asai M, Goshima F, Murata T, Shimizu N, Ito Y, Kimura H

    Oncotarget   Vol. 7 ( 47 ) page： 76793-76805   2016.11

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.18632/oncotarget.12529

    PubMed

  24. Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor. Reviewed

    Murata T, Noda C, Narita Y, Watanabe T, Yoshida M, Ashio K, Sato Y, Goshima F, Kanda T, Yoshiyama H, Tsurumi T, Kimura H

    Journal of virology   Vol. 90 ( 8 ) page： 3873-3889   2016.4

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1128/JVI.03227-15

    PubMed

  25. The Epstein-Barr virus BRRF2 gene product is involved in viral progeny production. Reviewed

    Watanabe T, Tsuruoka M, Narita Y, Katsuya R, Goshima F, Kimura H, Murata T

    Virology   Vol. 484   page： 33-40   2015.10

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.virol.2015.05.010

    PubMed

  26. The Epstein-Barr Virus BDLF4 Gene Is Required for Efficient Expression of Viral Late Lytic Genes. Reviewed

    Watanabe T, Narita Y, Yoshida M, Sato Y, Goshima F, Kimura H, Murata T

    Journal of virology   Vol. 89 ( 19 ) page： 10120-10124   2015.10

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1128/JVI.01604-15

    PubMed

  27. Roles of Epstein-Barr virus BGLF3.5 gene and two upstream open reading frames in lytic viral replication in HEK293 cells. Reviewed

    Watanabe T, Fuse K, Takano T, Narita Y, Goshima F, Kimura H, Murata T

    Virology   Vol. 483   page： 44-53   2015.9

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.virol.2015.04.007

    PubMed

  28. A Herpesvirus Specific Motif of Epstein-Barr Virus DNA Polymerase Is Required for the Efficient Lytic Genome Synthesis. Reviewed

    Narita Y, Sugimoto A, Kawashima D, Watanabe T, Kanda T, Kimura H, Tsurumi T, Murata T

    Scientific reports   Vol. 5   page： 11767   2015.6

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/srep11767

    PubMed

▼display all

To the head of Papers.▲

MISC 2

  1. S-like-phase cyclin-dependent kinases stabilize the Epstein-Barr virus BDLF4 protein to temporally control late gene transcription Reviewed

    Sato Y, Watanabe T, Suzuki C, Abe Y, Abdullah Al Masud H.M, Inagaki T, Yoshida M, Suzuki T, Goshima F, Adachi J, Tomonaga T, Murata T, Kimura H.

    Journal of Virology   Vol. 93 ( 8 )   2019

    　More details

  2. The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas Reviewed

    Suzuki M, Takeda T, Nakagawa H, Iwata S, Watanabe T, Siddiquey M.N.A, Goshima F, Murata T, Kawada J.-I, Ito Y, Kojima S, Kimura H.

    Frontiers in Microbiology   Vol. 6 ( APR )   2015

    　More details

To the head of MISC.▲

Presentations 3

  1. 新型コロナウイルスの最新知見から 歯科における対応を考える Invited

    名東区歯科医師会学術講演会  2021.3.25 

    　More details

    Event date： 2021.3

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

    Venue：ウェブ開催  

  2. 新型コロナウイルスについて −ウイルス学と歯科臨床の両方の視点で− Invited

    愛知県歯科医学大会  2021.2.21  (公社) 愛知県歯科衛生士会

    　More details

    Event date： 2021.2

    Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

    Venue：愛知県歯科医師会館およびWeb開催  

  3. 診療室における感染予防の 基本と実際 Invited

    R2年度“卒後1～3年のための研修会”  2021.1.10  公益社団法人　愛知県歯科衛生士会

    　More details

    Event date： 2021.1

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

    Venue：愛知県歯科医師会館およびWeb開催  

To the head of Presentations.▲

Research Project for Joint Research, Competitive Funding, etc. 7

  1. Epstein-Barrウイルスが有する核酸認識受容体を介した自然免疫応答からの回避機構の解析

    2021

    堀科学芸術振興財団 

  2. EBウイルスにより細胞老化制御機構の解明

    2020

    共済団 医学研究奨励助成金 

  3. 遺伝子変異型EBVの造腫瘍性において果たす意義を解明する

    2019

    北村記念血液疾患研究基金 

    　 More details

    Grant type：Competitive

  4. 網羅的プロテオーム解析で解くEBウイルス発癌の分子機構

    2019

    第４４回がんその他の悪性新生物研究助成金 

    　 More details

    Grant type：Competitive

  5. ヒト化マウスモデルを用いた EBV 関連リンパ増殖症に対する新たな標的治療の評価

    2018.4 - 2019.3

    那須基金 

    　 More details

    Grant type：Competitive

  6. 平成30年度 海外学会等参加費用援助 (International Conference on EBV & KSHV 2018)

    2018

    第24回日本医学会総会記念医学振興基金 

    　 More details

    Grant type：Competitive

  7. ヒト化マウスを用いたEpstein-Barr ウイルス感染症の病態解析

    2016.10 - 2018.3

    GSKジャパン研究助成 

    　 More details

    Grant type：Competitive

▼display all

To the head of Research Project for Joint Research, Competitive Funding, etc..▲

KAKENHI (Grants-in-Aid for Scientific Research) 4

  1. EBウイルスの病原体認識回避機構の解明

    Grant number：21K15449  2021.4 - 2024.3

    若手研究

    渡辺 崇広

    　 More details

    Authorship：Principal investigator 

    Grant amount：\4680000 （ Direct Cost: \3600000 、 Indirect Cost：\1080000 ）

    Epstein-Barr virus (EBV) は、生体防御を担う免疫応答を巧みにコントロールし、免疫平衡の状態で生涯感染を維持することができる。この免疫平衡状態が何らかの理由で破綻すると、EBV関連がんを発症する。本研究では、EBV遺伝子発現ライブラリを用いて特に自然免疫制御機構に着目したスクリーニングを行い、この過程に関わるウイルス因子を同定する。さらに同定したウイルス因子を標的とした遺伝子組換えウイルスを構築し、EBVの造腫瘍性を再現したヒト化マウスモデルを用いたin vivoでの検証を実施し、生体におけるEBVと自然免疫との共進化および発がん機構の解明を推進する。

  2. 欠失EBVによるリンパ腫発生機構の解明

    Grant number：20H03493  2020.4 - 2023.3

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    木村 宏

    　 More details

    Authorship：Coinvestigator(s) 

    我々は慢性活動性Epstein-Barr virus (EBV) 感染症に対して、網羅的遺伝子解析を行い、高率にEBV遺伝子の一部が欠失していることを発見した。本研究では、欠失ウイルスがEBV関連腫瘍で普遍的にみられる事象なのか、一部の疾患に限定しているのかを明らかにする。具体的には、様々なEBV関連腫瘍の腫瘍組織を集積し、Whole EBVシーケンシングを行う。この過程で、疾患特異的に欠失しているEBV遺伝子を同定する。次いで、それらのEBV遺伝子を欠失した変異ウイルスを再現・作成し、培養細胞を用いたin vitroおよびヒト化マウスを用いたin vivoモデルにより、当該遺伝子の役割を解明する。

  3. ヒト化マウスモデルを用いたEBV関連リンパ増殖症の病態解析と新たな標的治療の評価

    2018.4

    科学研究費補助金 

    　 More details

    Authorship：Principal investigator 

  4. 遺伝子改変EBウイルスとヒト化マウスを用いたリンパ増殖性疾患の発症病理の解析

    2016.10 - 2018.3

    科学研究費補助金 

To the head of KAKENHI (Grants-in-Aid for Scientific Research).▲

Industrial property rights 1

  1. Cyclin dependent kinase(CDK)阻害剤によるEpstein-Barrウイルスのウイルス産生抑制

    佐藤好隆、木村宏、渡辺崇広

    　More details

    Application no：特願2017-250093  Date applied：2017.12

    Country of applicant：Domestic  

To the head of Industrial property rights.▲
 

Teaching Experience (On-campus) 3

  1. ウイルス学総論4

    2020

  2. ウイルス学総論6

    2020

  3. ウイルス学実習

    2020

To the head of Teaching Experience (On-campus).▲